Document is current
Any future updates will be listed below
-
Authors
Bergens, Matthew A.
Braun, Matthew
Johnson, Ernaya J. https://orcid.org/0000-0001-8249-6801
Li, Yan
Myers, Jamie S.
Qalbani, Anushay Z. https://orcid.org/0009-0002-9884-4764
Smith, Patrick
Bush, Amy T.
Hill, Lauren
Pires, Andrea
Alyea, Edwin P.
Chao, Nelson J. https://orcid.org/0000-0001-6725-7220
Choi, Taewoong https://orcid.org/0000-0003-3776-2407
Gasparetto, Cristina
Hong, Sanghee
Horwitz, Mitchell E. https://orcid.org/0000-0001-9863-8464
Long, Gwynn D.
Lopez, Richard D.
Ramalingam, Sendhilnathan
Sarantopoulos, Stefanie
Sullivan, Keith M. https://orcid.org/0000-0002-1379-9216
Sung, Anthony D. https://orcid.org/0000-0003-3765-641X
- License Information
-
More Information
Article History
Received: 13 August 2025
Revised: 29 November 2025
Accepted: 26 March 2026
First Online: 4 April 2026
Competing interests
: Dr Sung’s work has been funded by Merck, Novartis, Enterome, and Seres. He has received research product for studies from DSM/iHealth, Clasado, and BlueSpark Technologies. He has consulted for Targazyme, Acrotech, Geron, and Janssen. None of the parties mentioned provided funding for this study.
: All methods were performed in accordance with the relevant guidelines and regulations. CPOP was implemented as a standard of care program. Therefore, patients were not consented as data was collected as part of routine care. The Duke Health Institutional Review Board approved the analysis of data collected as a quality improvement (QI) study (Pro00111631).
